Peter Loftus is a reporter for The Wall Street Journal in Philadelphia covering the pharmaceutical and medical-device ...

Shares of Becton Dickinson & Co. BDX advanced 1.05% to $204.45 Thursday, on what proved to be an all-around positive trading ...

The US Court of Appeals for the Federal Circuit affirmed a Patent Trial & Appeal Board unpatentability determination, finding that a skilled ...

Becton, Dickinson and Company (BD) has received the US Food and Drug Administration’s (FDA) 510(k) clearance for the Phasix ...

Shares of Becton Dickinson & Co. BDX rose 1.22% to $202.32 Wednesday, on what proved to be an all-around favorable trading ...

Traders have long known Donald Trump intended to use tariffs as a tool for economic policy. Citigroup Inc., a year ago, even ...

Piper Sandler analyst Jason Bednar lowered the firm’s price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Becton Dickinson (BDX – Research Report), ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance ...

Former Edwards Lifesciences Critical Care Unit, renamed BD Advanced Patient Monitoring, yesterday launched the HemoSphere ...

On April 15, 2025, the U.S. Court of Appeals for the Federal Circuit (“CAFC”) affirmed the Patent Trial and Appeal Board’s (“Board”) decision ...

BD introduces next generation hemodynamic monitoring solution providing clinicians with AI-driven clinical decision support: ...